Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

The research leading to these results received funding from the Obra Social “la Caixa” (to ME), the Cellex Foundation (to ME), the European Union's Horizon 2020 research and innovation programme under grant agreement No 727264 Epipharm (to ME), the 2015 Endowment fund for Research into Respiratory Health (“Fonds de Dotation Recherche en Santé Respiratoire”; to MD), the “Fondation ARC pour la recherche sur le cancer - Aide individuelle” (to MD), the Spanish Association Against Cancer (to VD), the Pla Estratègic de Recerca i Innovació en Salut (to SM), the Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (PI16/01821 to LMM and PI15/02223, to IG-B), RETTICS grant (RD12/0036/0040 to IG-B), Fundación Merck Salud (to IG-B), Departamento de Salud, Gobierno de Navarra (074-2017, to IGB), the European Commission MSCA IMMUNOMARK-799818 (to IBara), the China Scholarship Council and Karolinska Institutet Fonder (to QX), and the Health and Science Departments of the Generalitat de Catalunya (to ME). We thank IGTP–HUGTP Biobank (PT13/0010/0009) University Hospital Ramon y Cajal-IRYCIS Biobank (PT13/0010/0002), members of the Spanish National Biobanks Network of the Instituto de Salud Carlos III, Andalusia Public Health System Biobank, the Biological Resource Center of the Hospices Civils de Lyon (Tissu-tumorothèque Est), and the Tumor Bank Network of Catalonia for their help with the collection of samples.